Solidified self-nanoemulsifying formulation for oral delivery of combinatorial therapeutic regimen: part II in vivo pharmacokinetics, antitumor efficacy and hepatotoxicity
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Solidified self-nanoemulsifying formulation for oral delivery of combinatorial therapeutic regimen : part II in vivo pharmacokinetics, antitumor efficacy and hepatotoxicity. / Jain, Amit K; Thanki, Kaushik; Jain, Sanyog.
In: Pharmaceutical Research, Vol. 31, No. 4, 04.2014, p. 946-58.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Solidified self-nanoemulsifying formulation for oral delivery of combinatorial therapeutic regimen
T2 - part II in vivo pharmacokinetics, antitumor efficacy and hepatotoxicity
AU - Jain, Amit K
AU - Thanki, Kaushik
AU - Jain, Sanyog
PY - 2014/4
Y1 - 2014/4
N2 - PURPOSE: The present work focuses on the in vivo evaluation of tamoxifen and quercetin combination loaded into solid self-nanoemulsifying drug delivery system (s-Tmx-QT-SNEDDS).METHODS: Lyophilization was employed to prepare s-Tmx-QT-SNEDDS using Aerosil 200 as carrier. The developed formulation was evaluated for in vitro cell cytotoxicity, in vivo pharmacokinetics, antitumor efficacy and toxicity studies.RESULTS: In vivo pharmacokinetics revealed ~8-fold and ~4-fold increase in oral bioavailability of tamoxifen and quercetin, respectively as compared to free counterparts. s-Tmx-QT-SNEDDS exhibited significantly higher cell cytotoxicity, as compared to free drug combination revealing ~32-fold and ~22-fold higher dose reduction index for tamoxifen and quercetin, respectively estimated using median effect dose analysis. s-Tmx-QT-SNEDDS could suppress tumor growth in DMBA induced tumor bearing animals by ~80% in contrast to ~35% observed with tamoxifen citrate. The significant appreciation in antitumor efficacy was further supported by normalized levels of tumor angiogenesis markers (MMP-2 and MMP-9). Finally, complete obliteration in tamoxifen induced hepatotoxicity was observed upon administration of developed formulation in contrast to that of clinically available tamoxifen citrate when measured as function of hepatotoxicity markers and histopathological changes.CONCLUSIONS: In nutshell, co-encapsulation of quercetin with tamoxifen in solid SNEDDS poses great potential in improving the therapeutic efficacy and safety of tamoxifen.
AB - PURPOSE: The present work focuses on the in vivo evaluation of tamoxifen and quercetin combination loaded into solid self-nanoemulsifying drug delivery system (s-Tmx-QT-SNEDDS).METHODS: Lyophilization was employed to prepare s-Tmx-QT-SNEDDS using Aerosil 200 as carrier. The developed formulation was evaluated for in vitro cell cytotoxicity, in vivo pharmacokinetics, antitumor efficacy and toxicity studies.RESULTS: In vivo pharmacokinetics revealed ~8-fold and ~4-fold increase in oral bioavailability of tamoxifen and quercetin, respectively as compared to free counterparts. s-Tmx-QT-SNEDDS exhibited significantly higher cell cytotoxicity, as compared to free drug combination revealing ~32-fold and ~22-fold higher dose reduction index for tamoxifen and quercetin, respectively estimated using median effect dose analysis. s-Tmx-QT-SNEDDS could suppress tumor growth in DMBA induced tumor bearing animals by ~80% in contrast to ~35% observed with tamoxifen citrate. The significant appreciation in antitumor efficacy was further supported by normalized levels of tumor angiogenesis markers (MMP-2 and MMP-9). Finally, complete obliteration in tamoxifen induced hepatotoxicity was observed upon administration of developed formulation in contrast to that of clinically available tamoxifen citrate when measured as function of hepatotoxicity markers and histopathological changes.CONCLUSIONS: In nutshell, co-encapsulation of quercetin with tamoxifen in solid SNEDDS poses great potential in improving the therapeutic efficacy and safety of tamoxifen.
KW - Administration, Oral
KW - Animals
KW - Antineoplastic Agents
KW - Chemistry, Pharmaceutical
KW - Combinatorial Chemistry Techniques
KW - Drug Delivery Systems
KW - Emulsifying Agents
KW - Female
KW - Humans
KW - Liver
KW - MCF-7 Cells
KW - Nanoparticles
KW - Random Allocation
KW - Rats
KW - Rats, Sprague-Dawley
KW - Tamoxifen
KW - Journal Article
KW - Research Support, Non-U.S. Gov't
U2 - 10.1007/s11095-013-1214-1
DO - 10.1007/s11095-013-1214-1
M3 - Journal article
C2 - 24135934
VL - 31
SP - 946
EP - 958
JO - Pharmaceutical Research
JF - Pharmaceutical Research
SN - 0724-8741
IS - 4
ER -
ID: 168217640